BTCY

Biotricity, Inc. Common Stock

BTCY

Market cap $10M

Delisted

BTCY was delisted on the 2nd of August, 2024.

Back to rankings

About: Biotricity Inc is a medical technology company that focuses on biometric data monitoring solutions. It aims to deliver remote monitoring solutions to the healthcare & consumer markets, with a focus on diagnostic and post-diagnostic solutions for lifestyle and chronic illnesses. Biotricity is expanding medical-grade monitoring into the consumer market via its Biolife solution, which empowers users to self-manage chronic conditions. Its products include Bioflux, which is a mobile cardiac telemetry (MCT) device that provides real-time monitoring and transmission of ambulatory patients' ECG information; Biocare Telemed; Bioheart, which is a personal heart monitor; Biokit, and Biocare health.

Employees: 55

Healthcare Medical Instruments & Supplies

Financial journalist opinion

Zacks Investment Research

Are Medical Stocks Lagging Biotricity (BTCY) This Year?

Here is how Biotricity Inc. (BTCY) and Brainsway Ltd. Sponsored ADR (BWAY) have performed compared to their sector so far this year.

Are Medical Stocks Lagging Biotricity (BTCY) This Year?

Zacks Investment Research

Biotricity (BTCY) Upgraded to Buy: Here's Why

Biotricity (BTCY) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Biotricity (BTCY) Upgraded to Buy: Here's Why

Biotricity Reinforces Growth Trajectory, Kicking Off Fiscal 2026 with Strong First Quarter Results Featuring Revenue Growth, Positive EBITDA and Improved Margins

REDWOOD CITY, CA, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Biotricity Inc. (OTCQB:BTCY) ("Biotricity" or the "Company”), an innovative Technology-as-a-Service (TaaS) company committed to redefining the landscape of the healthcare industry with state-of-the-art remote monitoring and diagnostic solutions, today announced its financial results for its first quarter of fiscal 2026, ended June 30, 2025. Dr. Waqaas Al-Siddiq, Biotricity Founder & CEO, said, "We're proud to deliver another quarter of strong performance and a shift to positive EBITDA, which demonstrates the scalability of our business model and strength of our team. Management believes that this a foundational milestone for Biotricity, exemplifying our ability to grow our business as we go from a loss-producing startup to a business that can operate profitably. Following a massive year of positive transformation for Biotricity, we continue to harness the power of workflow automation, AI technology, and other technological enhancements to further improve our operational expenses, margins, and revenues. This powerful combination has set the foundation to fuel ongoing growth. In doing so, we demonstrate our ability to scale with strategic focus and long-term sustainability. The expansion of our Cardiac AI Cloud platform, empowered by strategic partnerships with industry giants, showcases our commitment to revolutionizing medical diagnostics and consumer healthcare. Leveraging over 2 trillion beats of anonymized data, our AI-driven platform is set to enhance clinic profitability, paving the way for transformative advancements in diagnostic accuracy and patient outcomes. Importantly, we remain on track to pursue FDA clearance for our groundbreaking AI clinical model in the coming months.

Biotricity Reinforces Growth Trajectory, Kicking Off Fiscal 2026 with Strong First Quarter Results Featuring Revenue Growth, Positive EBITDA and Improved Margins

Biotricity to Host Fiscal 2026 First Quarter Financial Results and Business Update Call on August 14th

Company to announce continued Revenue Growth, Improvements in Margins, Operational Efficiency, and a shift to positive EBITDA

Biotricity to Host Fiscal 2026 First Quarter Financial Results and Business Update Call on August 14th

BTCY: CA: A Fun Idea With Yield But Risky

The Purpose Bitcoin Yield ETF (BTCY:CA) generates income by writing call options on Bitcoin, sacrificing some upside for current yield. This strategy suits investors seeking income from Bitcoin, but not those focused on maximizing capital appreciation from BTC's price growth. BTCY:CA offers a high distribution yield (around 17.7%), but comes with significant volatility and liquidity concerns, including a wide bid/ask spread.

BTCY: CA: A Fun Idea With Yield But Risky

Biotricity, Inc. (BTCY) Q4 2025 Earnings Conference Call Transcript

Biotricity, Inc. (OTC:BTCY) Q4 2025 Earnings Call July 18, 2025 4:45 PM ET Company Participants S. John Ayanoglou - Chief Financial Officer Waqaas Al-Siddiq - Founder, President, CEO & Chairman Conference Call Participants Michael John Donovan - H.C.

Biotricity, Inc. (BTCY) Q4 2025 Earnings Conference Call Transcript

Biotricity Delivers Strong Fiscal Year 2025 Results with Revenue Growth, Continued Margin Improvement, and Reduced Operating Expenses, Putting Profitability within Reach

REDWOOD CITY, CA, July 17, 2025 (GLOBE NEWSWIRE) -- Biotricity Inc. (OTCQB:BTCY) ("Biotricity" or the "Company"), a Technology-as-a-Service (TaaS) company that offers innovative diagnostic, chronic disease, and lifestyle management solutions for healthcare providers and consumers, today announced its financial results for the fourth quarter and fiscal year ended March 31, 2025.

Biotricity Delivers Strong Fiscal Year 2025 Results with Revenue Growth, Continued Margin Improvement, and Reduced Operating Expenses, Putting Profitability within Reach

Biotricity to Host Fiscal 2025 Fourth Quarter Financial Results and Business Update Call on July 18th

Company to announce improvements in Margins, Operational Efficiency, and a shift to positive Adjusted EBITDA REDWOOD CITY, Calif., July 15, 2025 (GLOBE NEWSWIRE) -- Biotricity Inc. (OTCQB:BTCY), an innovative Technology-as-a-Service (TaaS) company committed to redefining the landscape of the healthcare industry with state-of-the-art remote monitoring and diagnostic solutions, will host its Fiscal 2025 Fourth Quarter Financial Results and Business Update Call on July 18, 2025.

Biotricity to Host Fiscal 2025 Fourth Quarter Financial Results and Business Update Call on July 18th

Biotricity Recognized by Financial Times as One of 2025's Fastest-Growing Companies in the Americas, Growing 256.4% Over the Period Analyzed

REDWOOD CITY, Calif., April 08, 2025 (GLOBE NEWSWIRE) -- Biotricity Inc. (OTCQB: BTCY) a leading Technology-as-a-Service (Taas) company specializing in cutting-edge diagnostic and chronic disease management solutions for healthcare providers and consumers, is proud to announce its inclusion on the Financial Times' list of The Americas' Fastest-Growing Companies 2025 . This recognition highlights Biotricity's innovation in digital health and exceptional growth of 256.4% during a period marked by unprecedented global challenges.

Biotricity Recognized by Financial Times as One of 2025's Fastest-Growing Companies in the Americas, Growing 256.4% Over the Period Analyzed

Biotricity Expands IP Portfolio & Strategy with 14 New Patents, Reinforcing Innovation & Leadership in Remote Monitoring, Diagnostics, & Chronic Disease Management

Biotricity's latest patents focus on a multi-biometric device platform that functions as both a patch and watch, advancing biometric monitoring solutions for remote patient care.

Biotricity Expands IP Portfolio & Strategy with 14 New Patents, Reinforcing Innovation & Leadership in Remote Monitoring, Diagnostics, & Chronic Disease Management

See News Rankings

Charts implemented using Lightweight Charts™